• Specx

  Participated · Series A · Jun 2026

  Specx develops hyperspectral imaging technology that analyzes wavelength data from light and has built an end-to-end platform covering satellite observation data acquisition, processing, and analysis. The startup aims to commercialize this hyperspectral capability for space applications and has pursued both public R&D and private investment to do so. It was discovered through Jeju Center for Creative Economy & Innovation’s 2024 Pre-Startup Package and became the inaugural investment of the center’s jointly managed Jeju Early-Stage Startup Fund. Specx was selected for the Deep Tech TIPS program, receiving KRW 1.5 billion in R&D funding. On June 19, Specx closed a KRW 3 billion follow-on pre-Series A round led by Triangle Partners with participation from E&Venture Partners and JX Partners. The combined public and private funding is intended to advance commercialization and further development of its hyperspectral imaging offerings.

• Autonomous A2Z

  Participated · Equity · Mar 2026

  Autonomous A2Z develops autonomous vehicle technologies with a hybrid engineering approach that combines rule-based algorithms and AI-driven decision systems aimed at achieving Level 4 autonomy. The company operates a research center in Pyeongchon, Gyeonggi, and runs autonomous mobility projects in markets including Singapore (in partnership with Grab), the United Arab Emirates, and Japan, where it has begun robotaxi trials. It has accumulated total funding of 122.5 billion won following the recent 40.5 billion won pre-IPO round and is preparing for a Kosdaq listing. Planned uses of capital include expanding domestic and international projects and procuring sensors, controllers, and vehicle components. Autonomous A2Z is preparing to participate in a large-scale pilot program led by the South Korea Ministry of Transport. The company says it aims to accelerate commercial deployment of Level 4 driverless vehicles and to build a global data network to support that goal.

• Poen

  Participated · Series B · Jul 2024

  POEN develops technology to select and remanufacture reusable cells from used electric-vehicle batteries and assembles remanufactured battery modules and packs. The company has built an EV battery value-chain platform in partnership with major industry players including Hyundai Motor, Kia, LG Energy Solution, SK ON, and CATL. POEN plans to accelerate development and commercialization of battery modules and packs and to expand its global presence supplying remanufactured batteries to key markets. It has established subsidiaries in the United States and Germany and positions itself as a leader in eco-friendly battery recycling and resource recovery. The company has received industry recognition including a CES Innovation Award and the ‘Best Innovation Award for Used Batteries’ at InterBattery. Since its founding in 2019, POEN has raised a total of 46.7 billion KRW to date.

• MEZOO

  Participated · Series B · Nov 2023

  Meju develops HiCardi, a remote patient real-time monitoring platform used for continuous vital-sign tracking. The company has commercial partnerships including a domestic distribution agreement with 동아ST and a memorandum with HL만도 to develop Digital Healthcare Automotive solutions. Meju is expanding HiCardi beyond healthcare into industrial safety monitoring for construction and factory workers and is in final negotiations with a Korean public enterprise for product supply. Financially, Meju reported approximately ₩1.4bn in revenue in 2022, is targeting ₩4.0bn in 2023, and aims for ₩10.0bn in revenue by 2025 to reach breakeven. Its investors have cited the company’s technology, commercialization progress, and growth potential when committing capital.

• BIORCHESTRA

  Participated · Series C · Feb 2022

  Biorchestra is an RNA therapeutics company based in Daejeon, South Korea, and Cambridge, Massachusetts. It develops RNA-based therapeutics using a BMD platform that can control microRNAs which regulate multiple messenger RNAs involved in disease. The company has developed a proprietary drug delivery system (BDDS™) for commercial drug development and reports IV-delivered ASO knock-down efficacy in cortex, hippocampus, striatum and spinal cord. Leadership includes CEO Branden (Jinhyeob) Ryu, CMO and US President Dr. Louis O’Dea, and CFO Young-Gil Kim. Biorchestra plans to use new funding to expand R&D and its product pipeline, complete a GMP facility, and initiate nonclinical toxicology programs. The company raised $45M in Series C financing to support these activities.

No current team members are available.